Gonadotropins belong to the family of dimeric glycoprotein hormones and regulate gonadal physiology mediated by G protein-coupled, seven-transmembrane receptors. These glycoprotein hormones are widely used in the clinic to promote ovarian follicle development and for treating some cases of male infertility. We traced the coevolution of dimeric gonadotropin hormones and their receptors, together with thyrotropin and its receptor. We updated recent findings on human genetic variants of these genes and their association with dizygotic twining, polycystic ovarian syndrome, primary ovarian insufficiency, male-limited precocious puberty, and infertility. In addition to the known physiological roles of gonadotropin-receptor signaling in gonadal tissues, we also discussed emerging understanding of extragonadal functions of gonadotropins in bones and adipose tissues, together with recent advances in in vivo imaging of gonadotropin receptors in live animals. Recent development of gonadotropin receptor agonists and antagonists were summarized with an emphasis on the development of functional antagonists for FSH receptors to alleviate osteoporosis and obesity associated with menopause.
Dimeric gonadotropins and their seven transmembrane receptors: structures and coevolution
Human body expresses three gonadotropins (LH, luteinizing hormones; FSH, follicle stimulating hormone, and hCG: human chorionic gonadotropins). These circulating hormones share a common alpha subunit but possess different beta subunits (β-LH, β-FSH, and β-CG) [1] . All subunits belong to the large family of cystine-knotcontaining proteins consisting of a basic structure of four cysteine residues with a spacing of Cys-(X)3-Cys and Cys-X-Cys important for forming a ring structure containing eight amino acids. Inclusion of two additional cysteines allows the formation of a third disulfide bond penetrating the ring structure, thus resulting in a cystine knot with 10 amino acids of which six are cysteine residues [2] . Formation of the knot structure leads to severe steric hindrance for the overall conformation of these proteins and serves as ideal structures for receptor binding.
The common α subunit forms noncovalent heterodimers with different β subunits (LH-β, FSH-β, and CG-β). In addition to heterodimeric LH, FSH, and hCG, thyroid stimulating hormone (TSH) also shares the common α-subunit that heterodimerizes with the β-TSH subunit [1] . Searching the human genome allowed us to identify two additional human glycoprotein hormone (GPH)-like genes, α2 (A2) and β5 (B5) [3] . Using a yeast two-hybrid assay, the two subunits were found as potential heterodimerization partners but A2 and B5 did not interact with other GPH subunits. Immunological analyses confirmed the heterodimerization of A2 and B5 in transfected cells and their colocalization in the anterior pituitary. Heterodimeric A2/B5 glycoproteins, named as thyrostimulin, activate human TSH receptors, but not LH and FSH receptors [3] . In human, there are five heterodimers with subunits from α and β gene families ( Figure 1) ; they constitute the family of GPHs because all of them have N-linked carbohydrate side chains. In addition, O-linked glycosylation is present in the β subunit of hCG, responsible for the prolonged in vivo half-life of hCG [4] .
The human genome sequence is a remarkable example of the combinatorial reuse of available, evolutionarily conserved protein domains forming more complex proteins. During evolution, gene duplication allowed the derivation of paralogous genes with one of them retaining the function of the ancestral gene and the other one evolving modified sequences and functions in a process known as neo-functionalization [5] . Gene duplication can occur by tandem duplication due to replication slippage or unequal recombination as well as duplication of whole genome or large parts thereof. When tandem duplication has created paralogs, closely related members are tightly linked in the same chromosome (e.g., LH and FSH receptors are both located in human chromosome 2p16.3, whereas LH-β and six copies of CG-β genes are clustered in chromosome 19q13 [6] ). Either through changes in coding sequence or changes in regulatory regions, duplicate copies obtain new and tissue-specific functions.
Tracing the evolutionary origin of GPHs, one can hypothesize that a single cystine-knot-containing gene evolved first, and the ancient GPH could be monomers or dimers. This was followed by gene duplication and the evolution of α and β subunit genes, leading to the generation of functional heterodimers (Figure 1 ). Later on, both α and β subunit genes went through another round of duplication, leading to ancestral α2 and β5 genes. For the α subgroup of GPH genes, the common α and α2 (A2) persist in the human genome, whereas the β subunit gene went through two additional rounds of duplication, leading to the formation of β-TSH, β-LH, and β-FSH. During primate evolution, the β-LH gene went through several more rounds of duplication to derive the β-CG genes ( Figure 1 ). In the human genome, there are single copies of the above-mentioned GPH subunit and receptor genes except the presence of multiple copies of CG-β genes [7] , consistent with the recent origins of CG-β genes with minimal time for gene loss.
GPH receptors are seven-transmembrane, G-protein-coupled receptors expressed in the plasma membrane. Tracing the evolution of three receptors binding GPHs, one can hypothesize that one ancestral GPH receptor interacted with one ancestral monomeric or homodimeric GPH. Subsequently, duplication of the ancestral GPH receptor led to the evolution of TSH and gonadotropin receptors capable of interacting with TSH and the ancestral gonadotropin, respectively. This was followed by the duplication of the gonadotropin receptor gene into LH and FSH receptor genes activated by LH/hCG and FSH, respectively ( Figure 1 ).
During hundreds of millions of years, GPHs coevolved with their specific G protein-coupled receptors to perform distinct physiological functions. Because GPHs have common ancestors, key amino acid sequences and functional domains are retained in these ligands. Similarly, the GPH receptors retained their seven-transmembrane structures, extracellular leucine-rich repeats, and key residues. It is interesting to note that many of these paralogous ligands, at high, nonphysiological concentrations, could still activate paralogous receptors (e.g., LH on FSH receptors and vice versa) [8, 9] . Furthermore, a mutation in the transmembrane domain of the FSH receptor gene is associated with a familial case of recurrent spontaneous ovarian hyperstimulation syndrome [10] . In vitro characterization of the mutated FSH receptor revealed that its specificity had decreased, responding to hCG in addition to FSH.
In addition to vertebrates, GPH-like subunits and their corresponding receptors were also found in invertebrates. In particular, orthologs for glycoprotein protein A2 and B5 subunit genes have been identified in diverse animal phyla, including the nematodes, chordates, hemichordates, arthropods, mollusks, echinoderms, and annelids [11] . In invertebrates, A2/B5 heterodimers play a developmental role and may function in water and mineral balance. Of interest, in vitro experiments showed that heterodimeric human GPH A2 (GPA2) and B5 (GPB5) could activate fly leucine-rich repeatcontaining G protein-coupled receptor-1 (DLGR1) orthologous to [12] , demonstrating the retention of key residues for ligand-receptor interactions during evolution. Because insects do not have a circulatory system and associated endocrine signaling, one can hypothesize that ancient GPHs originally played paracrine/autocrine roles in the common ancestors of vertebrates and invertebrates. Findings of oocyte-derived thyrostimulin (A2/B5 heterodimer) and granulosa cell-expressed TSH receptor in the mammalian ovary [13] could represent a "vestigial" paracrine system in vertebrates. In addition to the evolution of paralogous genes with modified sequences and functions, changes in the promoter/enhancer regions of GPH and receptor genes allowed the evolution of tissue-specific expression of a given ligand or receptor. Loss of ligand gene expression at tissues coexpressing receptors in ancestral animals conferred the evolution of endocrine signaling for gonadotropins in present-day vertebrates.
Genetic variants of gonadotropins and their receptors: associated phenotypes
FSH secreted by the anterior pituitary regulates gonadal functions by binding to specific receptors in granulosa cells of ovarian follicles and Sertoli cells of testicular seminiferous tubules. Similarly, pituitary-derived LH controls gonadal functions by interacting with its receptors in theca, luteal, and mature granulosa cells in the ovary. In the testis, LH acts exclusively on Leydig cells. Essential roles of gonadotropins and their receptors in gonadal development based on studies in rodent models have been reviewed [14, 15, 16, 17] and will only briefly discussed here. The FSH-FSH receptor signaling is essential for female fertility because null mice lacking the FSH-β ligand [18] or FSH receptor gene [19, 20] are sterile. FSH-deficient females showed a block in folliculogenesis prior to antral follicle formation. In contrast, FSH-deficient males are fertile despite having small testes [18] . Female FSH receptor-deficient mice showed thin uteri, small ovaries, and total block of folliculogenesis before antral follicle formation. Ovarian histology demonstrated normal thecal layer, defects in folliculogenesis including degenerating antral follicles, and absence of corpora lutea [19] . FSH receptor-deficient males are fertile, displaying small testes and partial spermatogenic failure with a blockage at the round spermatid stage [20] . Likewise, LH-LH receptor signaling is essential for female and male fertility. Targeted disruption of LH-β leads to hypogonadism, defects in gonadal steroidogenesis, and infertility. Mutant female mice were hypogonadal and defective in folliculogenesis, whereas mutant males had decreased testes size, Leydig cell hypoplasia, reduced testosterone levels, and blockage of spermatogenesis [21] . Likewise, targeted disruption of the LH receptor gene led to infertility in both male and female mice [22, 23] . Serum estradiol and progesterone levels decreased in females, whereas testosterone levels decreased in males. Abnormalities included ambiguous vaginal opening, abdominal testes, micropenis, decreased weights of the gonads, arrested follicular growth beyond antral stage, disarray of seminiferous tubules, hypotrophy of Leydig cells, and spermatogenic arrest beyond the round spermatid stage. Due to the essential roles of gonadotropins and their receptors in the propagation of the species, extensive investigations on genetic variants of these genes have been performed in infertile, subfertile, and high fecundity patients [15] . We updated recent findings dealing with human genetic variants and associated phenotypes for gonadotropins and their receptors (Table 1) . It is interesting to note that no germ line inactivating mutations in the common-α or hCG-β subunits are known in patients, likely due to essential roles of hCG during implantation and embryonic development.
In patients, inactivating mutations in FSH-β gene are known, leading to primary amenorrhea and absence of follicular maturation in females [24] as well as hypogonadism in men [25] . Likewise, mutations in the extracellular ligand-binding domain of the FSH receptor gene were found in patients with hereditary hypergonadotropic ovarian failure [26] . Expression of the mutant gene in transfected cells demonstrated a dramatic reduction of ligand-binding capacity and signal transduction. Furthermore, mutations in either extracellular domain [27, 28] , extracellular loop 2 in the transmembrane region [29] , or heterozygotic mutations [30] of the FSH receptor gene were associated with delayed puberty, primary amenorrhea, and small ovaries. Variants in the noncoding regions of FSH-β [31] or FSH receptor [32] gene are also associated with polycystic ovarian syndrome, whereas a missense mutation in the FSH receptor is associated with primary ovarian insufficiency [33] . The heterozygous Ala307Thr variation in the FSH receptor is present in women who develop polycystic ovarian syndrome (PCOS) and is associated with a higher responsiveness to exogenous FSH [34] . Based on FSH stimulation of ovarian responses in patients, FSH receptor Gly29Ala [35] , Thr307Ala [36] , and Ser680Asn [37] polymorphisms were found to be associated with lower follicle growth responses induced by FSH.
For LH-LH receptor signaling, inactivating mutations of LH-β or LH receptor cause infertility in women and men [38] . Women with inactivating mutations in these genes have similar clinical manifestations characterized by normal or late menarche followed by oligoamenorrhea and infertility. Inactivating mutations of the LH receptor gene are also associated with amenorrhea or oligomenonrrhea, enlarged cystic ovaries, and infertility [39] . For the rare empty follicle syndrome, point mutations in the LH receptor coding region (Asn400Ser or Ala449Thr) were found in different populations [40, 41] . In addition, a V-LH-β variant was found in different populations, and recombinant form of this variant displayed higher biopotency in vitro but shorter half-life in circulation [42] . Although the 312N variant of the LH receptor gene conferred up to 2.7-fold increased risk of polycystic ovary syndrome in a Sardinian population [43] and the Trp28Arg/Ile35Thr LH-β gene variants were associated with elevated testosterone levels in women with polycystic ovary syndrome [44] , these findings likely represent rare cases and await further confirmation.
In males, mutations in the LH-β genes were associated with impairment in pre-and postnatal testosterone secretion, delayed puberty, defective spermatogenesis, and infertility [45, 46] . In contrast, genetic male patients with LH receptor mutations showing the severe form of LH resistance have predominantly female external genitalia and absence of secondary sex differentiation at puberty (46XY disorder of sexual differentiation or male pseudohermaphroditism), together with impaired Leydig cell differentiation and testosterone production [47] . Also, patients with milder forms have predominantly male external genitalia with micropenis and/or hypospadias or only infertility without ambiguity. An inactivating mutation of the LH receptor with impaired membrane trafficking also led to Leydig cell hypoplasia [48, 43] . Although mutations for paired ligand and receptor genes usually exhibit similar phenotypes, less severe phenotypes found in patients with LH-β gene mutations as compared with those with LH receptor mutations are likely due to fetal activation of Leydig cell proliferation, differentiation, and testosterone production by placental hCG, thus minimizing the need of LH for male differentiation.
Due to the unique seven-transmembrane structures of FSH and LH receptors, mutations of key residues in transmembrane V and VI domains as well as the hinge region between leucine-rich repeatscontaining extracellular and seven-transmembrane domains led to gain of function of these receptors. Mutated receptors showed constitutive activity in the absence of cognate ligands [49, 50] . Three naturally occurring mutations in the transmembrane region of the FSH receptor have been identified in three families with recurrent spontaneous pregnancy-associated, ovarian hyperstimulation syndrome [51, 52] . A mutation in the transmembrane domain of the FSH receptor gene is associated with a familial case of ovarian hyperstimulation [10] due to the ability of the mutant receptor to respond to hCG. In males, an activating mutation of the FSH receptor sustains spermatogenesis in a hypophysectomized man [53] whereas another activating FSH receptor mutation was found in a patient with normal testicular function but without detectable serum FSH [54] . Similar gain-of-function mutations in the LH receptor gene led to male-limited precocious puberty [48] . In severe cases of somatic LH receptor mutations, Leydig-cell tumors were found [55] . Of interest, mothers of male-limited precocious puberty patients carrying the same mutation showed normal fertility [56] , suggesting that elevated androgen biosynthesis by constitutively activated LH receptor has minimal impact on follicle development. It is likely that aromatase activity in granulosa cells is rate limiting for estrogen biosynthesis despite increased androstenedione produced by theca cells. For comprehensive analyses of sequence-structure-function analysis of gonadotropin receptors, an online database (SSFA-GPHR) is available [57] .
Extensive genome-wide association studies (GWAS) have been performed to investigate association between specific phenotypes and unique single nucleotide polymorphisms (SNPs). These SNPs are usually in the noncoding regions and serve as markers in the genome to denote genetic changes in the neighboring haplotype, a set of DNA variations that tend to be inherited together. Polymorphisms near FSH receptor and LH receptor genes are associated with polycystic ovarian syndrome [32, 58, 59, 60, 61] , the most important ovarian disease affecting reproductive age women.
Spontaneous dizygotic twinning occurs in 1-4% of women, with familial clustering. Although FSH receptor was not linked to dizygotic twinning in selective families [62] , a GWAS analysis involving 1980 mothers of spontaneous dizygotic twins identified one SNP (rs1103106) near the FSH-β gene [63] . Based on ∼90 000 births in Iceland, the risk of a mother delivering twins increased by 18% for each copy of allele rs11031006-G. In addition to twinning, this allele was associated with higher serum FSH levels, earlier age at menarche, earlier age at first child, higher lifetime parity, lower polycystic ovarian syndrome risk, and earlier age at menopause. Although GWAS studies only revealed correlation between specific SNPs and phenotypes under investigation, one can speculate that the stretch of DNA near selective SNP carries mutations in the promoter or enhancer of neighboring genes, leading to alterations of gene expression. Different SNPs identified could alter expression of LH and FSH receptors in PCOS patients and increase levels of FSH-β in mothers of dizygotic twins.
Expression of gonadotropin receptors in extragonadal tissues and their physiological roles
In addition to gonads, FSH receptors are also expressed in extragonadal tissues [64] , including the uterus and placenta [65] (Figure 2) . Also, several reports demonstrated expression of FSH receptors on endothelial cells of the tumor vasculature in patients [66, 67] , together with actions of FSH on monocytes [68, 69] and human umbilical vein endothelial cells [70] . Recently, functional FSH receptors were found in human and mouse fat tissues and adipocytes; treatment with FSH increased fat accumulation through the Gai/Ca2 + /CREB pathway [71] . In bones, FSH acted on osteoclasts by stimulating FSH receptors via a nonclassical Gi protein signaling pathway and regulated bone mass in mice [72, 73] . However, FSH actions on bone osteoclasts were controversial due to difficulties in confirming the expression of FSH receptors in osteoclasts [74, 75] . This issue was recently resolved using near infrared imaging of FSH receptors in different bone structures in live animals [76] as described below.
Compared with the FSH receptor, LH receptors are expressed in more extragonadal tissues, including the uterus, oviducts, cervix, mammary gland, adrenal, placenta, embryos, bladder, prostate, seminal vesicle, and certain brain regions [77, 78] (Figure 2) . In human myometrium, treatment with hCG decreased connexin-43 expression in myometrial cells via protein kinase A signaling [79] . Infusion of hCG into the uterine cavity of normal cycling baboons during the window of uterine receptivity induced morphological and biochemical changes in the endometrium [80] . In addition, LH receptor mRNAs were found in stromal cells of the endometrium [81] , endothelial and smooth muscle cells of human uterine arteries [82] , and some brain regions [83, 84] . Treatment with LH/hCG promoted endometrial angiogenesis and growth [85] , enhancement of blastocysts implantation [86] as well as increases in oviduct gene expression [87] . Despite findings of LH receptors in the reproductive tract, fertility is restored in LH receptor null mice after transplantation of wildtype ovarian tissues, indicating extragonadal LH receptors are not essential for reproduction [88] . It is important to note that most data on extragonadal gonadotropin actions were derived from animal experiments. A woman with inactivating, compound heterozygous LH receptor mutations (i.e., without functional LH receptors) became pregnant with oocyte donation [89] , also indicating extragonadal LH receptors are not essential for pregnancy.
Live imaging of gonadotropin receptors
Imaging in the near infrared-II (NIR-II) window can probe centimeters tissue depth in vivo and achieve micron-scale spatial resolution at millimeters depth with reduced photon scattering and autofluorescence in tissues [90, 91] . For monitoring follicle growth, routine use of ultrasound imaging allows detection of antral and preovulatory follicles in the clinic [92] , but imaging of smaller follicles is difficult. Because primary and secondary follicles express FSH receptors [93] , we recently conjugated a near infrared probe CH1055 to FSH and detected specific NIR-II signals in cultured granulosa cells exposed to the CH1055-FSH conjugate. After injecting this FSH-fluorophore in vivo, we imaged secondary and larger follicles inside ovaries and whole testes in living mice [76] . Because the fluorophore CH1055 used has low cell toxicity and was rapidly cleared from the body, this approach could be adopted for future clinical use. Infrared imaging of ovaries could be valuable for detecting the presence of preantral follicles in patients with low ovarian reserve because ovaries in 50% of patients with primary ovarian insufficiency still contain preantral follicles and could be activated by in vitro incubation with Aktstimulating agents before grafting back to patients [94, 95] .
Bones in our body undergo rapid turnover, with osteoclasts responsible for new bone formation and osteoclasts decreasing bone mass [96] . Increased incidence of osteoporosis in postmenopausal women has been attributed to a lack of ovarian estrogen secretion but serum FSH increases dramatically in this population due to a lack of negative feedback of ovarian estrogens and inhibins at the hypothalamic-pituitary axis. An earlier study demonstrated functional FSH receptors in osteoclasts responsible for bone breakdown [97] , suggesting that elevated serum FSH, and not decreased estrogen secretion, in postmenopausal women is responsible for osteoporosis. However, follow-up reports could not replicate findings of FSH receptor expression in mouse-cultured osteoclasts or bones [75, 98] . Due to difficulties involved in studying osteoclasts embedded in the rigid bone structure, these studies relied upon reverse transcription PCR and immunostaining analyses of isolated osteoclasts and their precursors expressing extremely low levels of FSH receptors. Recently, the use of NIR-II fluorophore conjugated to FSH allowed imaging of FSH receptors in diverse bone structures in live animals of both sexes [76] (Figure 3) . Our ability to detect FSH receptors in live animals conclusively demonstrated competitive and ligandspecific FSH binding to bones [76] . These findings are consistent with the observed lack of osteoporosis in FSH-β or FSH receptor null mice lacking FSH or its receptor, despite decreases in circulating estrogens. Furthermore, increased bone formation was found in FSH-β heterozygotes mice with normal estrogen secretion but lower FSH levels [72] . In postmenopausal women, FSH receptor gene polymorphisms are associated with changes in bone mineral density and turnover [99] , underscoring the importance of FSH in the induction of osteoporosis.
We further used IR-FEPC, a newly developed Near infrared-II (NIR-II) fluorophore, for conjugation with hCG to investigate LH receptor expression in vivo. After exposure to conjugated hCG@IR-FEPC, specific NIR-II signals were found in lysates of ovaries from gonadotropin-treated female mice and in testis of males [100] . Injection of hCG@IR-FEPC allowed competitive and time-dependent noninvasive imaging of ovaries in live immature gonadotropinprimed and adult female mice. Ex vivo confocal fluorescence imaging analyses demonstrated hCG signals in theca, granulosa, and luteal cells. Of interest, NIR-II signals were also found in uterus of immature mice pretreated with eCG but not pretreated with eCG followed by hCG, suggesting uterus in the proliferative, but not secretory, phase expressed high levels of LH receptors. This approach allows future in vivo monitoring of gonadal and extragonadal LH receptors under different physiological states.
It is important to note that rodent studies on FSH actions in bone and adipose tissues await confirmation using human tissues. Because moderate obesity protects against bone loss in postmenopausal women [101] , further studies are needed to reveal the exact roles of postmenopausal FSH elevation in obesity and osteoporosis. 
Development of gonadotropin agonists and antagonists
Recombinant FSH, LH, and hCG are widely used for infertility treatment [102, 103] . FSH is used for stimulating follicle growth, whereas hCG or LH are used in inducing ovulation or treating male patients with hypogonadotropic hypogonadism. As compared with FSH and LH, newly evolved hCG found only in primates has much longer circulating half-life due to O-linked glycosylation sites in the C-terminal end of CG-β. By fusing the C-terminal tail of hCG-β to the C-terminus of FSH-β, a long-acting FSH was developed [104] , leading to the commercialization of this FSH agonist capable of achieving overall live birth rate comparable to recombinant FSH [105] . A single injection of this long-acting FSH replaces daily administration of regular FSH for 1 week [106] . Major efforts have been made to elucidate crystal structure of gonadotropins and their receptors [107, [108] [109] [110] as well as mechanisms of gonadotropin receptor activation [14, 49, 50] . These studies allowed design of small molecular weight agonists and antagonists for gonadotropins [111] . For FSH agonists, several selective, nonpeptide, small molecules have been identified [112, 113] , but their actions in patients remain uncertain. For LH agonists, the most advanced study demonstrated that a single oral intake of a lowmolecular-weight LH agonist induced ovulation of the preovulatory follicle in pituitary-suppressed female volunteers [114] . In addition, selective, nonpeptide antagonists to FSH receptors have been generated with a compound capable of inhibiting ovulation in immature and cycling adult rats [115] . However, the use of small molecular weight gonadotropin agonists or antagonists faces the challenges of enormous costs for testing their efficacy, potential side effects due to off-target activation, and safety in primate models and patients.
Earlier attempts were made to generate gonadotropin antibodies as contraceptives. Although antibodies against fragments of hCG have been tested as a contraceptive vaccine [116] , this approach was terminated due to a lack of efficacy. Immunization against fragments of FSH-ß [117] or FSH receptor [118] was also proposed as nonsteroidal contraceptives in both males and females. However, these approaches also suffered from lack of efficacy and uncertain long-term outcomes. Increased bone turnover in postmenopausal women is a major determinant of osteoporosis [119] . Because serum FSH levels are elevated drastically after menopause in women and FSH receptors are expressed in osteoblasts of different bone structures [97, 76] , elevated serum FSH is possibly responsible for menopausal bone loss. Indeed, a blocking antibody to the β-subunit of FSH prevented bone loss in rodents by inhibiting bone resorption and stimulating bone synthesis [120] . Menopause is also linked to an increase in fat mass and decreases in lean mass exceeding age-related changes. Earlier studies indicated that obesity after menopause could be reversed by sex hormone replacement therapy [121] . Because functional FSH receptors are expressed in adipose tissues [71] , effects of sex hormone replacement could be mediated by corresponding suppression of serum FSH. Recently, a polyclonal antibody targeting the β-subunit of FSH was found to reduce adipose tissue in mice, cause profound beiging, increase cellular mitochondrial density, activate brown adipose tissue, and enhance thermogenesis [122] . These studies underscore the possibility of minimizing osteoporosis and obesity in postmenopausal women by blocking FSH actions.
Large N-terminal extracellular (ecto-) domains of GPH receptors are responsible for ligand binding [49] . In addition to the use of antibodies to antagonize FSH actions, ectodomains of gonadotropin receptors could be used as functional antagonists. We fused the ectodomains of LH or FSH receptors to the single-transmembrane domain of CD8 and found that hybrid proteins anchored on the cell surface retained high-affinity ligand binding [123] . Inserting a junctional thrombin cleavage site in the hybrid molecules allowed generation of soluble receptor fragments capable of interfering with gonadotropin binding to their receptors and blocking cAMP production stimulated by gonadotropins. When administered to rats, the soluble FSH receptor fragment retarded testis growth and induced apoptosis. These findings suggest that soluble ligand-binding regions of gonadotropin receptors could selectively neutralize actions of FSH and LH.
Although estrogen and progesterone replacement therapy was used in menopausal women to prevent hot flash and other menopausal symptoms, a large population study by Women's Health Initiative in the USA showed that overall health risks exceeded benefits based on outcome of coronary heart disease [124] . In addition, the Million Women Study in UK indicated that hormonal replacement therapy is associated with an increased risk and incidence of fatal breast cancer [125] . Although GnRH agonists are effective in suppressing FSH secretion in postmenopausal women, no improvement in bone parameters was evident [126] . The use of these compounds for treating osteoporosis in postmenopausal women requires further analyses. Because antibody neutralization studies demonstrated the role of elevated FSH in causing osteoporosis [97] and obesity [122] , FSH antibodies or ectodomains of the FSH receptor could have therapeutic potentials in postmenopausal women to enhance bone mass and decrease obesity in patients contraindicative for the estrogen replacement therapy.
